Johnson & Johnson's Fiscal Year is From January To December.
The item "Price-To-Sales-Ratio" stands at 4.62 as of 09/30/2025, the highest value at least since 06/30/2022, the period currently displayed.
As of the end of Johnson & Johnson's third quarter, the item "Price To Sales Ratio" stands at 4.62. This represents an increase of 15.90 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 8.73 percent compared to the value the year prior.
The 1 year change in percent is 8.73.
The 3 year change in percent is 22.59.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Sales Ratio | 905,699,262,464.00 |
![]() | AbbVie Inc - Price To Sales Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Sales Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Sales Ratio | 280,205,508,085.11 |
![]() | Novartis AG - Price To Sales Ratio | 255,096,620,580.91 |